FDA Determines Regulatory Review Period for OMNARIS Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the review period for OMNARIS, a human drug product, in order to extend its patent, as required by law. This decision follows a submission to the Director of Patents and Trademarks at the US Department of Commerce.